The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $39,351,458 in first-year total cost, median $9,021,816.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-G (O1)]1
- Special Emphasis Panel[ZAG1 ZIJ-G (O2)]1
- Special Emphasis Panel[ZRG1 BBBP-B (55)]1
Most frequent institutions
- COGNITION THERAPEUTICS, INC.1
- MEDICAL UNIVERSITY OF SOUTH CAROLINA1
- UNIVERSITY OF SOUTHERN CALIFORNIA1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months1R01AG065248-01 | AISEN, PAUL S.CATALANO, SUSAN MVAN DYCK, CHRISTOPHER H | COGNITION THERAPEUTICS, INC., PA | $24,533,829 | ZAG1 |
| 2020 | Life's end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial1R01AG068324-01 | MINTZER, JACOBOREYNOLDS, BRIGID | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $5,795,813 | ZRG1 |
| 2018 | Combination anti-amyloid therapy for preclinical Alzheimer's disease1R01AG061848-01 | AISEN, PAUL S.JOHNSON, KEITH A.SPERLING, REISA A. | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $9,021,816 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.